Published protocols Phase 2 trials (Jastreboff 2023, NEJM) evaluated weekly subcutaneous doses of 1, 4, 8, and 12 mg in obesity research cohorts
To evaluate the safety and tolerability of LY3437943, a study was conducted on 45 healthy subjects
FeelGood is a telehealth platform built around one core appeal: clinician-supervised GLP-1 treatment you can access from your phone without insurance, without a doctor's office, and without the $900-plus monthly price tag most people associate with these medications
Understanding the relationship between semaglutide and urinary changes helps patients distinguish normal treatment responses from symptoms requiring medical evaluation
Semaglutide has been on the market for over a decade for diabetes, and SELECT outcomes data extends past five years
Blood test markers to discuss with a clinician Marker IGF-1 Why it matters Tracks downstream GH-axis exposure from the CJC-1295 and ipamorelin components
